Frequency and determinants of use of antiretroviral and prophylactic therapies against Pneumocystis carinii pneumonia (PCP) before AIDS diagnosis in Italy

European Journal of Epidemiology

Volumn 14, Issue 1, 1998, Pages 41-47

  Napoli, Pier Angela ^a   Dorrucci, Maria ^a   Serraino, Diego ^b   Pezzotti, Patrizio ^a   Franceschi, Silvia ^b   Vella, Stefano ^a   Rezza, Giovanni ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Antiretroviral therapy; Epidemiological survey; Italy; Pneumocystis carinii Pneumonia (PCP); Prophylaxis

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; COTRIMOXAZOLE; DAPSONE; DIDANOSINE; METAKELFIN; PENTAMIDINE; PYRIMETHAMINE; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ARTICLE; CHILD; DRUG ABUSE; DRUG USE; FEMALE; GEOGRAPHIC DISTRIBUTION; HEMOPHILIA; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ITALY; MALE; PHYSICIAN; PNEUMOCYSTIS PNEUMONIA; PROPHYLAXIS; QUESTIONNAIRE; REGISTER;

EID: 0031931028     PISSN: 03932990     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007400519792     Document Type: Article

References (37)

1. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987; 317: 185-191.
2. Volberding PA, Lagakos SW, Kock MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990; 322: 941-949.
3. Fischl MA, Richman DD, Hansen N, et al. The safety and efficacy of Zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. Ann Intern Med 1990; 112: 727-737.
4. National Institute of Allergy and Infectious Diseases, National Institutes of Health, U.S. Public Health Service. State-of-the-Art Conference on Azidothymidine Therapy for Early HIV Infection. Am J Med 1990; 89: 335-344.
5. Sande MA, Carpenter CC, Cobbs CG, Holmes KK, Sanford JP. Antiretroviral Therapy for Adult HIV Infected Patients. Recommendations from a State-of-the Art Conference. National Institute of Allergy and Infectious Diseases State-of-the-Art Panel on Anti-Retroviral Therapy for Adult HIV-Infected Patients. JAMA 1993; 270: 2583-2589.
6. Aboulker JP, Swart AM and the Concorde Coordinating Committee. Preliminary analysis of the Concorde trial. Lancet 1993; 341: 889-890.
7. Volberding PA, Lagakos SW, Grimes JM, et al. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. N Engl J Med 1995; 333: 401-407.
8. Kahn JO, Lagakos SW, Richman DD, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992; 327: 581-587.
9. Fischl MA, Olson RM, Follansbee SE, et al. Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy. Ann Intern Med 1993; 118: 762-769.
10. Murray HW, Squires KE, Weiss W, et al. Stavudine in patients with AIDS and AIDS-related complex: AIDS clinical trials group 089. J Infect Dis 1995; 171 (Suppl. 2): 123-130.
11. Fischl MA, Stanley K, Collier AC, et al. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. Ann Intern Med 1995; 122: 24-32.
12. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995; 269: 696-699.
13. Delta Coordinating Committee. Delta: A randomized double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996; 348: 273-278.
14. Cameron B, Heath-Chiozzi M, Kravcik S, et al. Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir. 3rd Conference on Retroviruses and Opportunistic Infections. Washington, DC. January-February 1996.
15. Bartlett JG. Protease Inhibitors for HIV infection. Ann Intern Med 1996; 124: 1086-1088.
16. Lipsky JJ. Antiretroviral drugs for AIDS. Lancet 1996; 348: 800-803.
17. Richman DD. HIV Therapeutics. Science 1996; 272: 1886-1888.
18. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with Cd4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996; 335: 1081-1090.
19. Mellors JW, Rinaldo CR Jr, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272: 1167-1170.
20. Mellors JW, Kinsley LA, Rinaldo CR Jr, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995; 122: 573-579.
21. Saag MS, Holodniy M, Kuritzkes DR, et al. HIV viral load markers in clinical practice. Nat Med 1996; 2: 625-629.
22. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA 1996; 276: 146-154.
23. Centers for Disease Control: Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus. MMWR 1989; 38 (Suppl.5): 1-9.
24. Gallant JE, Moore RD, Chaisson RE. Prophylaxis for opportunistic infections in patients with HIV infection. Ann Intern Med 1994; 120: 932-944.
25. U.S. Public Health Service Task Force on Antipneumocystis Prophylaxis in Patients with Human Immunodeficiency Virus Infection. Recommendations for prophylaxis against Pneumocystis carinii Pneumonia for persons infected with Human Immunodeficiency Virus. J Acquir Immune Defic Syndr 1993; 6: 46-55.
26. Lundgren JD, Phillips AN, Pedersen C, et al. Comparison of long-term prognosis of patients with AIDS treated and not treated with Zidovudine. JAMA 1994; 271: 1088-1092.
27. Communicable Disease Report. The incidence and prevalence of AIDS and prevalence of other severe HIV disease in England and Wales for 1995 to 1999: Projections using data to the end of 1994. CDR review 1996; 6: R1-R24.
28. Dorrucci M, Pezzotti P, Phillips AN, Alliegro MB, Rezza G, and the HIV Italian Seroconversion Study Group. Antiretroviral treatment and progression to AIDS in HIV seroconverters from different risk groups. AIDS 1997; 11: 461-467.
29. Centro Operative Aids, Istituto Superiore di Sanità. Aggiornamento dei casi di AIDS notificatiin Italia al 31 Dicembre 1995. Notiziario Ist. Super. Sanità 1996; 9; 4 (Suppl. 1) (in Italian).
30. Ancelle-Park RA. Expanded European AIDS case definition. Lancet 1993; 341: 441.
31. Breslow NE, Day NE. The analysis of case-control studies. In: Statistical methods in cancer research, vol. 1. Lyons: IARC Scientific Publication, 1980.
32. Hosmer DW, Lemeshow S. Applied logistic regression. New York: John Wiley and Sons, Inc., 1989.
33. Phillips AN, Smith GD, Johnson MA. Will we ever know when to treat HIV infection? BMJ 1996; 313: 608-610.
34. Solomon L, Vlahov D, Astemborski J, Galai N, Graham NMH, Nelson KE. Factors associated with initiation of zidovudine in a cohort of injection drug users. J Drug Issues 1995; 25: 225-233.
35. D'Arminio Monforte A, Mainini F, Musicco M, et al. Impact of treatment and prophylaxis on presentation and survival of patients with AIDS in Milan. Lancet 1995; 346: 1488.
36. Porter K, Wall PG, Evans BG. Factors associated with lack of awareness of HIV infection before diagnosis of AIDS. BMJ 1993; 307: 20-23.
37. Crotti N. La migrazione sanitaria. Valutazione ed interpretazione del fenomeno: Problemi organizzativi ed assistenziali. In: La salute degli italiani: Rapporto 1991. Roma: La Nuova Italia Scientifica, 1991: 137-163 (in Italian).